tert-Butyl [2-(dimethylamino)ethoxy]acetate | 570398-23-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-Butyl [2-(dimethylamino)ethoxy]acetate
• 英文别名: tert-butyl 2-[2-(dimethylamino)ethoxy]acetate
• CAS: 570398-23-1
• 化学式: C₁₀H₂₁NO₃
• 分子量: 203.282
• InChiKey: SYUKNPFXTJSPSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N,N-二甲基乙醇胺 、 溴乙酸叔丁酯 以 四氢呋喃 、 mineral oil 为溶剂， 生成 tert-Butyl [2-(dimethylamino)ethoxy]acetate
  参考文献：
  名称：

  3-(Imidazolyl)-2-alkoxypropanoic acids

  摘要：

  根据公式（I）中的化合物，其中n为0-3，R1为可选择的取代C1-6烷基，C2-6烯基或C2-6炔基，杂环，芳香杂环，芳基或氢，而R2、R3、R4、R5、R6、R7、R8和R9分别独立选择自氢和可选择取代的C1-6烷基，或R5和R8为烷基链，是新颖的。它们在治疗与纤维蛋白沉积相关的血栓性疾病和其他病理条件中具有用途。

  公开号：

  US20030199522A1

文献信息

• 3-(imidazolyl)-2-alkoxypropanoic acids
  申请人：Allerton Charlotte Moira Norfor

  公开号：US06958402B2

  公开（公告）日：2005-10-25

  Compounds according to formula (I) wherein n is 0-3, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R 5 and R 8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition

  化合物按照式(I)制备，其中n为0-3，R1为可选取代的C1-6烷基、C2-6烯基或C2-6炔基、杂环、芳香杂环、芳基或氢，R2、R3、R4、R5、R6、R7、R8和R9各自独立地选自氢和可选取代的C1-6烷基，或R5和R8为烷基链。这些化合物是新颖的，可用于治疗血栓性疾病和与纤维蛋白沉积有关的其他病理情况。
• LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS
  申请人：Acuitas Therapeutics, Inc.

  公开号：US20190022247A1

  公开（公告）日：2019-01-24

  Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R 1 , R 2 , L, X, L, G 1 , G 2 , Z, a 1 , a 2 and n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
• LIPID NANOPARTICLE FORMULATIONS
  申请人：HARWOOD Erikc A.

  公开号：US20200121809A1

  公开（公告）日：2020-04-23

  Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.
• 3-(Imidazolyl)-2-alkoxypropanoic acids
  申请人：Pfizer Inc.

  公开号：US20030199522A1

  公开（公告）日：2003-10-23

  Compounds according to formula (I) wherein n is 0-3, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R 5 and R 8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  根据公式（I）中的化合物，其中n为0-3，R1为可选择的取代C1-6烷基，C2-6烯基或C2-6炔基，杂环，芳香杂环，芳基或氢，而R2、R3、R4、R5、R6、R7、R8和R9分别独立选择自氢和可选择取代的C1-6烷基，或R5和R8为烷基链，是新颖的。它们在治疗与纤维蛋白沉积相关的血栓性疾病和其他病理条件中具有用途。